View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 46. 1088
  • 2 Magyar Tudományos Akadémia – Semmelweis Egyetem Gasztroenterológiai és Endokrinológiai Kutatócsoport Budapest
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Az irritábilis bél szindróma (IBS) kezelése a változatos tünetek, a társuló neuropszichiátriai kórképek miatt nem könnyű feladat. Bár számos, különböző támadáspontú szert alkalmazunk a betegség kezelésére, a mai napig kevés olyan gyógyszer van, amelynek hatékonyságáról, biztonságosságáról és tolerabilitásáról egyértelmű bizonyítékok állnak rendelkezésre. Az IBS multikauzális jellegéből adódóan a visceralis hiperszenzitivitással, a motilitással, az agy-bél tengely szabályozási zavaraival kapcsolatos kutatások eredményei, a folyamatokban központi szerepet játszó neurotranszmitterek, ezek receptorainak megismerése teremtette meg az új kezelési lehetőségek alapját. Bár napjainkban néhány gyógyszert (alosetron, tegaserod) már törzskönyveztek egyes országokban IBS-ben, az új készítményekkel kapcsolatban még több, nagy betegszámú vizsgálatra van szükség.

  • Longstreth, G. F., Thompson, W. G., Chey, W. D. és mtsai: Functional bowel disorders. Gastroenterology, 2006, 130 , 1480–1491.

    Chey W. D. , 'Functional bowel disorders ' (2006 ) 130 Gastroenterology : 1480 -1491.

  • Barbara, G.: Irritable bowel syndrome. Gastroenterology Symposium/ Neurogastroenterology: From basic science to clinical application. Barcelona, 2005. 03. 12.

  • Spiller, R. C.: Irritable bowel syndrome. British Medical Bulletin, 2005, 72 , 15–29.

    Spiller R. C. , 'Irritable bowel syndrome ' (2005 ) 72 British Medical Bulletin : 15 -29.

  • Bearcroft, C. P., Perrett, D., Farthing, M. J.: Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut, 1998, 42 , 42–46.

    Farthing M. J. , 'Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study ' (1998 ) 42 Gut : 42 -46.

    • Search Google Scholar
  • Roka, R., Rosztoczy, A., Leveque, M. és mtsai: Fecal serin protease activity: a pathophysiological marker in diarrhea-predominant irritable bowel syndrome. Clin. Gastroenterol. Hepatol., 2006, in press.

  • Spiller, R. C.: Postinfectious irritable bowel syndrome. Gastroenterology, 2003, 124 , 1662–1671.

    Spiller R. C. , 'Postinfectious irritable bowel syndrome ' (2003 ) 124 Gastroenterology : 1662 -1671.

    • Search Google Scholar
  • Dunlop, S. P., Jenkins, D., Spiller, R. C.: Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am. J. Gastroenterol., 2003, 98 , 1578–1583.

    Spiller R. C. , 'Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome ' (2003 ) 98 Am. J. Gastroenterol. : 1578 -1583.

    • Search Google Scholar
  • Jackson, J. L., O’Malley, P. G., Tomkins, G. és mtsai: Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am. J. Med., 2000, 108 , 65–72.

    Tomkins G. , 'Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis ' (2000 ) 108 Am. J. Med. : 65 -72.

    • Search Google Scholar
  • Andresen, V., Camilleri, M.: Irritable bowel syndrome – recent and novel therapeutic approaches. Drugs, 2006, 66 , 1073–1088.

    Camilleri M. , 'Irritable bowel syndrome – recent and novel therapeutic approaches ' (2006 ) 66 Drugs : 1073 -1088.

    • Search Google Scholar
  • Gershon, M. D.: Review article: serotonin receptors and transporters: roles in normal and abnormal gastrointestinal motility. Aliment. Pharmacol. Ther., 2004, 20, Suppl. 7 , 3–14.

    Gershon M. D. , 'Review article: serotonin receptors and transporters: roles in normal and abnormal gastrointestinal motility ' (2004 ) 20 Aliment. Pharmacol. Ther. : 3 -14.

    • Search Google Scholar
  • Camilleri, M., Northcutt, A. R., Kong, S. és mtsai: Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo controlled trial. Lancet, 2000, 355 , 1035–1040.

    Kong S. , 'Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo controlled trial ' (2000 ) 355 Lancet : 1035 -1040.

    • Search Google Scholar
  • Camilleri, M., Chey, W. Y., Mayer, E. A. és mtsai: A randomised controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhoea predominant irritable bowel syndrome. Arc. Intern. Med., 2001, 161 , 1733–1740.

    Mayer E. A. , 'A randomised controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhoea predominant irritable bowel syndrome ' (2001 ) 161 Arc. Intern. Med. : 1733 -1740.

    • Search Google Scholar
  • Cremonini, F., Delgado-Aros, S., Camilleri, M.: Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomised controlled trials. Neurogastroenterol. Motil., 2003, 15 , 79–86.

    Camilleri M. , 'Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomised controlled trials ' (2003 ) 15 Neurogastroenterol. Motil. : 79 -86.

    • Search Google Scholar
  • Tack, J., Fried, M., Houghton, L. A. és mtsai: Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspective. Aliment. Pharmacol. Ther., 2006, 24 , 183–205.

    Houghton L. A. , 'Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspective ' (2006 ) 24 Aliment. Pharmacol. Ther. : 183 -205.

    • Search Google Scholar
  • Bradette, M., Monikes, H., Carter, F. és mtsai: Cilansteron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 month global study. Gastroenterology, 2004, 126 , A42 (abstract).

    Carter F. , 'Cilansteron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 month global study ' (2004 ) 126 Gastroenterology : A42 -.

    • Search Google Scholar
  • Fujita, T., Yokota, S., Sawada, M. és mtsai: Effect of MKC-733, a 5-HT receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study. J. Clin. Pharm. Ther., 2005, 30 , 611–22.

    Sawada M. , 'Effect of MKC-733, a 5-HT receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study ' (2005 ) 30 J. Clin. Pharm. Ther. : 611 -22.

    • Search Google Scholar
  • Mullner-Lissner, S. A., Fumagalli, I., Bardhan, K. D. és mtsai: Tegaserod a 5-HT 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment. Pharmacol. Ther., 2001, 15 , 1655–1666.

    Bardhan K. D. , 'Tegaserod a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation ' (2001 ) 15 Aliment. Pharmacol. Ther. : 1655 -1666.

    • Search Google Scholar
  • Novick, J., Miner, P., Krause, R. és mtsai: A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther., 2002, 16 , 1877–1888.

    Krause R. , 'A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation ' (2002 ) 16 Aliment. Pharmacol. Ther. : 1877 -1888.

    • Search Google Scholar
  • Morganroth, J., Ruegg, P. C., Dunger-Baldauf, C. és mtsai: Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am. J. Gastroenterol., 2002, 97 , 2321–2327.

    Dunger-Baldauf C. , 'Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects ' (2002 ) 97 Am. J. Gastroenterol. : 2321 -2327.

    • Search Google Scholar
  • Camilleri, M., McKinzie, S., Fox, J. és mtsai: Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin. Gastroenterol. Hepatol., 2004, 2 , 895–904.

    Fox J. , 'Effect of renzapride on transit in constipation-predominant irritable bowel syndrome ' (2004 ) 2 Clin. Gastroenterol. Hepatol. : 895 -904.

    • Search Google Scholar
  • Tack, J., Middleton, S. J., Horne, M. C. és mtsai: Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther., 2006, 23 , 1655–1665.

    Horne M. C. , 'Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome ' (2006 ) 23 Aliment. Pharmacol. Ther. : 1655 -1665.

    • Search Google Scholar
  • Tack, J., Broekaert, D., Fischler, B. és mtsai: A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut, 2006, 55 , 1095–1103.

    Fischler B. , 'A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome ' (2006 ) 55 Gut : 1095 -1103.

    • Search Google Scholar
  • Creed, F., Fernandes, L., Guthrie, E. és mtsai: The costeffectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology, 2003, 124 , 303–317.

    Guthrie E. , 'The costeffectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome ' (2003 ) 124 Gastroenterology : 303 -317.

    • Search Google Scholar
  • Creed, F.: How do SSRIs help patients with irritable bowel syndrome? Gut, 2006, 55 , 1065–1067.

    Creed F. , 'How do SSRIs help patients with irritable bowel syndrome? ' (2006 ) 55 Gut : 1065 -1067.

    • Search Google Scholar
  • Poynard, T., Regimbeau, C., Benhamou, Y.: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther., 2001, 15 , 355–361.

    Benhamou Y. , 'Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome ' (2001 ) 15 Aliment. Pharmacol. Ther. : 355 -361.

    • Search Google Scholar
  • Wallis, R. M.: Pre-clinical and clinical pharmacology of selective muscarinic M3 receptor antagonists. Life Sci., 1995, 56 , 861–868.

    Wallis R. M. , 'Pre-clinical and clinical pharmacology of selective muscarinic M3 receptor antagonists ' (1995 ) 56 Life Sci. : 861 -868.

    • Search Google Scholar
  • Dapoigny, M., Abitbol, J. L., Fraitag, B.: Efficacy of peripheral kappa agonist fedotozine versus placebo in the treatment of irritable bowel syndrome. A multicenter dose-response study. Dig. Dis. Sci., 1995, 40 , 2244–2248.

    Fraitag B. , 'Efficacy of peripheral kappa agonist fedotozine versus placebo in the treatment of irritable bowel syndrome. A multicenter dose-response study ' (1995 ) 40 Dig. Dis. Sci. : 2244 -2248.

    • Search Google Scholar
  • Callahan, M. J.: Irritable bowel syndrome Neuropharmacology. A review of approved and investigational compounds. J. Clin. Gastroenterol., 2002, 35 (Suppl.) , S58–S67.

    Callahan M. J. , 'Irritable bowel syndrome Neuropharmacology. A review of approved and investigational compounds ' (2002 ) 35 J. Clin. Gastroenterol. : S58 -S67.

    • Search Google Scholar
  • Gonenne, J., Camilleri, M., Ferber, I. és mtsai: Effect of alvimopan and codein on gastrointestinalk transit: a randomized controlled study. Clin. Gastroenterol. Hepatol., 2005, 3 , 784–791.

    Ferber I. , 'Effect of alvimopan and codein on gastrointestinalk transit: a randomized controlled study ' (2005 ) 3 Clin. Gastroenterol. Hepatol. : 784 -791.

    • Search Google Scholar
  • Paulson, D. M., Kennedy, D. T., Donovick, R. A. és mtsai: Alvimopan: an oral, peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction – a 21 day treatment-randomized clinical trial. J. Pain, 2005, 6 , 184–192.

    Donovick R. A. , 'Alvimopan: an oral, peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction – a 21 day treatment-randomized clinical trial ' (2005 ) 6 J. Pain : 184 -192.

    • Search Google Scholar
  • Tache, Y., Martinez, V., Million, M. és mtsai: Role of corticotropin releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome. Eur. J. Surg. Suppl., 2002, 587 , 16–22.

    Million M. , 'Role of corticotropin releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome ' (2002 ) 587 Eur. J. Surg. Suppl. : 16 -22.

    • Search Google Scholar
  • Zobel, A. W., Nickel, T., Kunzel, H. E. és mtsai: Effects of the high affinity corticotropine-releasing-hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res., 2000, 34 , 171–181.

    Kunzel H. E. , 'Effects of the high affinity corticotropine-releasing-hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated ' (2000 ) 34 J. Psychiatr. Res. : 171 -181.

    • Search Google Scholar
  • Chao, M. W., Rajagopal, R., Lee, F. S.: Neurotrophin signalling in health and disease. Clin. Sci. (Lond.), 2006, 110 , 167–173.

    Lee F. S. , 'Neurotrophin signalling in health and disease ' (2006 ) 110 Clin. Sci. (Lond.) : 167 -173.

    • Search Google Scholar
  • Parkmann, H. P., Rao, S. S., Reynold, J. C. és mtsai: Functional Constipation Study Investigators. Neurotrophin-3 improves functional constipation. Am. J. Gastroenterol., 2003, 98 , 1338–1347.

    Reynold J. C. , 'Functional Constipation Study Investigators. Neurotrophin-3 improves functional constipation ' (2003 ) 98 Am. J. Gastroenterol. : 1338 -1347.

    • Search Google Scholar
  • Awad, R. A., Llorens, F., Camelo, A. L. és mtsa: A randomized double-blind placebo-controlled trial of lidamidine HCL in irritable bowel syndrome. Acta Gastroenterol. Latinoam., 2000, 30 , 169–175.

    Camelo A. L. , 'A randomized double-blind placebo-controlled trial of lidamidine HCL in irritable bowel syndrome. Acta Gastroenterol ' (2000 ) 30 Latinoam. : 169 -175.

    • Search Google Scholar
  • Camilleri, M., Kim, D. Y., McKinzie, S. és mtsai: A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin. Gastroenterol. Hepatol., 2003, 1 , 111–121.

    McKinzie S. , 'A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome ' (2003 ) 1 Clin. Gastroenterol. Hepatol. : 111 -121.

    • Search Google Scholar
  • Song, G. H., Leng, P. H., Gwee, K. A. és mtsai: Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomized, double blind, placebo controlled study. Gut, 2005, 54 , 1402–1407.

    Gwee K. A. , 'Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomized, double blind, placebo controlled study ' (2005 ) 54 Gut : 1402 -1407.

    • Search Google Scholar
  • Chey, W. Y., Jin, H. O., Lee, M. H. és mtsai: Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am. J. Gastroenterol., 2001, 96 , 1499–1506.

    Lee M. H. , 'Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea ' (2001 ) 96 Am. J. Gastroenterol. : 1499 -1506.

    • Search Google Scholar
  • Cremonini, F., Camilleri, M., McKinzie, S. és mtsai: Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am. J. Gastroenterol., 2005, 100 , 652–663.

    McKinzie S. , 'Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study ' (2005 ) 100 Am. J. Gastroenterol. : 652 -663.

    • Search Google Scholar
  • Oh-Young, L., Mankata, J., Naliboff, B. D. és mtsai: A double-blind parallel group pilot study of the effects of CJ-11974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. Gastroenterology, 2000, 118 , A846 (abstract).

    Naliboff B. D. , 'A double-blind parallel group pilot study of the effects of CJ-11974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients ' (2000 ) 118 Gastroenterology : A846 -.

    • Search Google Scholar
  • Lordal, M., Navalesi, G., Theodorsson, E. és mtsai: A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br. J. Pharmacol., 2001, 134 , 215–223.

    Theodorsson E. , 'A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine ' (2001 ) 134 Br. J. Pharmacol. : 215 -223.

    • Search Google Scholar
  • Hasler, W. L., Soudah, H. C., Owyang, C.: A somatostatin analogue inhibits afferent pathways mediating perception of rectal distension. Gastroenterology, 1993, 104 , 1390–1397.

    Owyang C. , 'A somatostatin analogue inhibits afferent pathways mediating perception of rectal distension ' (1993 ) 104 Gastroenterology : 1390 -1397.

    • Search Google Scholar
  • Bradette, M., Delvaoux, M., Staomunt, G. és mtsai: Octreotid increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig. Dis. Sci., 1994, 39 , 1171–1178.

    Staomunt G. , 'Octreotid increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone ' (1994 ) 39 Dig. Dis. Sci. : 1171 -1178.

    • Search Google Scholar
  • Spiller, R.: Pharmacotherapy: non-serotonergic mechanism. Gut, 2002, 51 (Suppl. 1) , 87–90.

    Spiller R. , 'Pharmacotherapy: non-serotonergic mechanism ' (2002 ) 51 Gut : 87 -90.

  • Lubiprostone: RU0211, SPI0211. Drugs R D., 2005, 6, 245–248.

  • Pimentel, M., Chow, E. J., Lin, H. C.: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double blind, randomized, placebo-controlled study. Am. J. Gastroenterol., 2003, 98 , 412–419.

    Lin H. C. , 'Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double blind, randomized, placebo-controlled study ' (2003 ) 98 Am. J. Gastroenterol. : 412 -419.

    • Search Google Scholar
  • Pimentel, M., Chatterjee, S., Chow, E. J. és mtsai: Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig. Dis. Sci., 2006, 51 , 1297–1301.

    Chow E. J. , 'Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study ' (2006 ) 51 Dig. Dis. Sci. : 1297 -1301.

    • Search Google Scholar
  • Pimentel, M., Lin, H. C., Enayati, P. és mtsai: Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290 , G1089–1095.

    Enayati P. , 'Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity ' (2006 ) 290 Am. J. Physiol. Gastrointest. Liver Physiol. : G1089 -1095.

    • Search Google Scholar
  • Pimentel, M., Kong, Y., Park, S.: IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. Dig. Dis. Sci., 2004, 49 , 84–87.

    Park S. , 'IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen ' (2004 ) 49 Dig. Dis. Sci. : 84 -87.

    • Search Google Scholar
  • Niedzielin, K., Kordecki, H., Birkenfeld, B.: A controlled, double blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol., 2001, 13 , 1143–1147.

    Birkenfeld B. , 'A controlled, double blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome ' (2001 ) 13 Eur. J. Gastroenterol. Hepatol. : 1143 -1147.

    • Search Google Scholar

 

The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.

 

Mendeley citation style is available HERE.
  • Impact Factor (2019): 0.497
  • Scimago Journal Rank (2018): 0.176
  • SJR Hirsch-Index (2018): 20
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)
  • Impact Factor (2018): 0.564
  • Scimago Journal Rank (2018): 0.193
  • SJR Hirsch-Index (2018): 18
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)

Language: Hungarian

Founded in 1857
Publication: Weekly, one volume of 52 issues annually

Senior editors

Editor(s)-in-Chief: Papp Zoltán

Read the professional career of Papp Zoltán HERE.

 

Editorial Board

Click for the Editorial Board

Akadémiai Kiadó
Address: Prielle Kornélia u. 21-35. H-1117 Budapest, Hungary
Phone: (+36 1) 464 8235 ---- Fax: (+36 1) 464 8221
Email: orvosihetilap@akkrt.hu